Wong Daniel, Qiu Hongyu
Translational Cardiovascular Research Center, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA.
Translational Cardiovascular Research Center, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA; Clinical Translational Sciences (CTS) and Bio5 Institution, University of Arizona, Tucson, AZ 8572, USA.
Vascul Pharmacol. 2024 Dec;157:107443. doi: 10.1016/j.vph.2024.107443. Epub 2024 Nov 23.
Serum Response Factor (SRF) is a critical regulatory transcription factor widely expressed across cell types and is essential for animal survival. Excessive SRF activity has been linked to various pathological conditions and diseases, including cardiovascular diseases, cancers and neurodegenerative disorders, making the inhibition of SRF hyperactivity a promising therapeutic strategy. This review summarizes recent advancements in the discovery and development of SRF inhibitors, their regulatory mechanisms, and their respective molecular foundations. These insights deepen our understanding of current therapeutic potentials, paving the way for novel approaches to treat diseases associated with SRF hyperactivity.
血清反应因子（SRF）是一种关键的调控转录因子，在多种细胞类型中广泛表达，对动物生存至关重要。SRF活性过高与包括心血管疾病、癌症和神经退行性疾病在内的各种病理状况和疾病相关，因此抑制SRF的过度活性是一种很有前景的治疗策略。本文综述了SRF抑制剂的发现与开发、调控机制及其各自分子基础的最新进展。这些见解加深了我们对当前治疗潜力的理解，为治疗与SRF活性过高相关疾病的新方法铺平了道路。
